Newsroom
Sorted by: Latest
-
Ellington Credit Company Announces Offering of Unsecured Notes
OLD GREENWICH, Conn.--(BUSINESS WIRE)--Ellington Credit Company (NYSE: EARN) (the “Fund”) today announced the commencement of an underwritten public offering of unsecured notes due 2031 (the “2031 Notes”). The public offering price, interest rate, and other terms will be determined through negotiations between the Fund and the underwriters. The 2031 Notes have been rated ‘BBB’ by Egan-Jones Ratings Company, an independent rating agency unaffiliated with the Fund. The Fund intends to grant the u...
-
CSCI Continues Market Share Growth Despite Regional Housing Slowdown
BOYNTON BEACH, Fla.--(BUSINESS WIRE)--CSCI reports continued market share growth, expanding project volume as the residential construction market adjusts to changing economic conditions....
-
Uber Joins the Ibotta Performance Network in Exclusive, Multi-Year Partnership
DENVER & SAN FRANCISCO--(BUSINESS WIRE)--Ibotta, Inc. (NYSE: IBTA), the performance marketing platform for promotions, today announced a partnership with Uber Technologies, Inc. (NYSE: UBER) to deliver Ibotta-powered digital promotions across Uber’s grocery and retail ecosystem in the United States. This partnership strengthens the Ibotta Performance Network’s existing marketplace presence and gives CPG brands a direct path to shoppers at the final stage of the funnel — the point of purchase. T...
-
Thermo Fisher Scientific and SHL Medical Collaborate to Deliver Fully Integrated Drug-Device Solutions
RIDGEFIELD, N.J.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced a strategic collaboration with SHL Medical, a leading provider of advanced drug delivery systems, alongside an expansion of sterile fill-finish and autoinjector final assembly capacity at its Ridgefield, NJ site. Together, these investments establish a fully integrated U.S.-based offering spanning sterile manufacturing, device assembly and commercial packaging for drug-device c...
-
Kallisio Receives CE Mark for Stentra™ Precision Oral Immobilization System
BALTIMORE--(BUSINESS WIRE)--Kallisio has received CE certification for its Stentra™ oral immobilization system designed for precise, repeatable head and neck radiation therapy....
-
Radiant Logic Earns Two 2026 Cybersecurity Industry Awards for Identity Security Innovation
SAN FRANCISCO--(BUSINESS WIRE)--Radiant Logic, the pioneer of Identity Data Fabric and a leader in Identity Security Posture Management (ISPM), today announced it has received two 2026 cybersecurity industry awards recognizing its innovation and leadership in identity security. Radiant Logic was named a Gold Award winner in the Identity and Access Management (IAM) category of the 2026 Globee Cybersecurity Awards and was also named a Silver Award recipient in the ISPM category of the 2026 Cybers...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Indxx NextG UCITS ETF 24.03.2026 NXTG.LN IE00BWTNM743 170,002.00 USD 7,015,761.92 41.269 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Dow Jones International Internet UCITS ETF 24.03.2026 FDNI.LN IE00BT9PVG14 400,002.00 USD 7,190,284.72 17.976 ...
-
Scott Machut Joins Alliant Insurance Services’ Value-Based Healthcare and Risk Management Solutions Team
IRVINE, Calif.--(BUSINESS WIRE)--Scott Machut has joined Alliant Insurance Services as Senior Vice President with the Value-Based Healthcare and Risk Management Solutions team within its Employee Benefits Group, where he will focus on strategic growth. “Scott will play an active role in expanding our value proposition for the healthcare delivery market through analytics-driven risk management solutions,” said Kevin Overbey, President, Alliant Employee Benefits. “His experience will be instrumen...
-
Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared the first clinical results from two of its siRNA programs for neuromuscular diseases. Early results from Phase 1/2 ascending dose studies of SRP-1001 for facioscapulohumeral muscular dystrophy type 1 (FSHD1) and SRP-1003 for myotonic dystrophy type 1 (DM1) demonstrated dose- dependent muscle exposure, early biomarker effects, and favorable tolerab...